Clinical Data Another LAG-3 setback as Regeneron drug fails phase 3 trial PharmaphorumRegeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.OncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaphorum Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studiesNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026 Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
